Loading stock data…
USPH
$61.80+0.50 (+0.82%)
After Hours$61.80+0.00 (+0.00%)· Last close Jun 9
U.S.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
U.S. Physical Therapy, Inc. in the Healthcare sector is trading at $62.59. Wall Street consensus targets $93.67 (6 analysts), implying a +49.7% move over the next 12 months. The stock is currently near its 52-week low of $58.19, remaining 19.3% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +49.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$61.80
Potential Downside
0%
Whystock Fair Value$61.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Mean target$93.67+51.6%
Range$88.00 – $100.00
Fundamentals
U.S. Physical Therapy, Inc., together with its subsidiaries, operates and manages outpatient physical therapy clinics. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company provides pre-a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.20%
ROE
Average efficiency. Growth may require heavy reinvestment.
-0.44%
Volume
Today's trading volume
148,005
Recent News
How The Story Is Shifting For U.S. Physical Therapy (USPH) As Price Targets Reset
U.S. Physical Therapy’s fair value estimate has been reset from about US$106.83 to roughly US$93.67, marking a clear step down in the implied price target range. Analysts tying this move to recent commentary are balancing optimism around hospital alliances and Medicare rate support with more cautious views on profitability, leverage, and how quickly partnerships can translate into sustained margin gains. As you read on, you will see how this evolving narrative might shape your view of the...
3 Reasons USPH is Risky and 1 Stock to Buy Instead
U.S. Physical Therapy currently trades at $65.04 per share and has shown little upside over the past six months, posting a small loss of 4.3%. The stock also fell short of the S&P 500’s 11.6% gain during that period.
Do These 3 Checks Before Buying U.S. Physical Therapy, Inc. (NYSE:USPH) For Its Upcoming Dividend
Readers hoping to buy U.S. Physical Therapy, Inc. ( NYSE:USPH ) for its dividend will need to make their move shortly...
Stocks making big moves yesterday: Helios, DraftKings, CACI, U.S. Physical Therapy, and Ulta
Check out the companies making headlines yesterday:
U.S. Physical Therapy’s Q1 Earnings Call: Our Top 5 Analyst Questions
U.S. Physical Therapy’s first quarter results were met with a sharp negative market reaction, reflecting investor concerns over margin compression and profit performance. Management attributed the quarter's margin decline primarily to severe winter weather, which led to over 31,000 lost patient visits and higher fixed costs, as well as upfront investments in new initiatives. CEO Christopher J. Reading acknowledged that, despite robust demand and higher commercial reimbursement rates, these headw